Article
Immunology
Robert J. Wong, Harvey W. Kaufman, Justin K. Niles, Hema Kapoor, Robert G. Gish
Summary: Current treatment eligibility algorithms for chronic hepatitis B are complex and may contribute to missed opportunities for early antiviral therapy. Using a large US laboratory database, we propose a stepwise simplification of chronic hepatitis B treatment eligibility to be considered, aiming to improve timely treatment.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Virology
Elisabetta Loggi, Stefano Gitto, Filippo Gabrielli, Elena Franchi, Hajrie Seferi, Carmela Cursaro, Pietro Andreone
Summary: More than 250 million people are currently infected with hepatitis B worldwide. New therapeutic approaches are rapidly developing and promise to eliminate infected cells and cure the infection completely. New virological tools are being evaluated for on-treatment monitoring of these innovative antiviral treatments.
Article
Gastroenterology & Hepatology
Hye-Lin Kim, Gi-Ae Kim, Jae-A Park, Hye-Rim Kang, Eui-Kyung Lee, Young-Suk Lim
Summary: This study found that starting antiviral therapy in the immune-tolerant phase is more cost-effective compared with delaying treatment until the active hepatitis phase in CHB patients, especially with increasing hepatocellular carcinoma risk, decreasing drug costs, and consideration of productivity loss.
Article
Gastroenterology & Hepatology
Xiaoli Wu, Zhenzhen Yao, Xin Lai, Yingping Gu, Songxu Peng
Summary: This study investigated the associations between age at treatment initiation and treatment outcomes in children with chronic hepatitis B (CHB). The study found that younger age at treatment initiation was associated with higher rates of HBsAg loss and HBeAg clearance.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Vinh Vu Hai, Yusuke Shimakawa, Jin Kim, Hai Do Ngoc, Quang Le Minh, Didier Laureillard, Maud Lemoine
Summary: The study found that a large proportion of patients with chronic HBV infection in Vietnam require antiviral therapy, and using the TREAT-B score is a better alternative to indicate treatment eligibility compared to the simplified WHO criteria.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Immunology
Tamsin Cargill, Eleanor Barnes
Summary: Chronic hepatitis B infection is a serious global health threat, and new treatments are urgently needed. Therapeutic vaccination aims to induce or boost existing HBV-specific immune responses to control HBV infection, but strategies to improve vaccine efficacy are still under exploration.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2021)
Article
Gastroenterology & Hepatology
Guiqiang Wang, Zhongping Duan
Summary: The Chinese Society of Infectious Diseases and the Chinese Society of Hepatology convened an expert panel in 2019 to update guidelines for the prevention and treatment of chronic hepatitis B (CHB), in order to support the actual situation in China. These guidelines aim to provide support for the prevention, diagnosis, and treatment of CHB.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Hailemichael Desalegn, Stian Magnus Staurung Orlien, Hanna Aberra, Eyerusalem Mamo, Sine Grude, Kristina Hommersand, Nega Berhe, Svein Gunnar Gundersen, Asgeir Johannessen
Summary: This pilot program demonstrates the long-term benefits of CHB therapy in a resource-limited setting. The high mortality in patients with cirrhosis underscores the need for earlier detection of CHB and timely initiation of antiviral treatment in sub-Saharan Africa.
Article
Gastroenterology & Hepatology
Si Ho Kim, Eun Ju Cho, Boo-ok Jang, Kyunghan Lee, Jae Kyun Choi, Gwang Hyeon Choi, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Yun Bin Lee, Jeong-Hwan Yoon, Jin-Wook Kim, Sook-Hyang Jeong, Eun Sun Jang
Summary: This multicenter cohort study aimed to compare the real-world biochemical response rates during tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), and entecavir (ETV) treatment in patients with chronic hepatitis B virus (HBV) infection. The study found that ETV was more effective for older patients with negative e-antigen and underlying comorbidities, while metabolic factors such as fatty liver, obesity, and diabetes significantly affected biochemical responses in patients treated with ETV, TAF, and TDF. Further investigation is needed to understand the mechanisms behind the higher biochemical response rate in patients treated with ETV.
LIVER INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Meng-Lan Wang, Xiu-Jun Yin, Xue-Lian Li, Fa-Da Wang, Jing Zhou, Ya-Chao Tao, Yong-Hong Wang, Dong-Bo Wu, En-Qiang Chen
Summary: This study indicates that the use of NAC may help improve intrahepatic cholestasis and coagulation dysfunction in patients with HBV-ACLF.
FRONTIERS IN MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Fangwan Yang, Yujuan Liu, Baimei Zeng, Jun Chu, Han Hu, Yanqing Yang, Huan Chen, Caiyun Tian, Ying Li, Shide Lin
Summary: The Lok index has strong predictive accuracy for progression to ACLF in patients with acute exacerbation and severe exacerbation of chronic HBV infection, requiring different thresholds of liver fibrosis based on severity of liver injury.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Hyeyeon Hong, Minjoo Cho, Chaeyeon Lim, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Summary: Patients with chronic hepatitis B (CHB) on nucleos(t)ide analogues (NUCs), especially those on tenofovir disoproxil fumarate (TDF), face a higher risk of chronic kidney disease (CKD) progression compared with untreated patients. However, patients treated with entecavir and tenofovir alafenamide (TAF) have comparable CKD progression risks to untreated patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Kazumasa Sakamoto, Kiyoaki Ito, Hiroshi Yotsuyanagi, Hiroshi Yatsuhashi, Yasuhito Tanaka, Shuhei Hige, Yasuhiro Takikawa, Yoshiyuki Ueno, Kazuhide Yamamoto, Fumio Imazeki, Jun Inoue, Masayuki Kurosaki, Takeji Umemura, Hidenori Toyoda, Eiji Mita, Kojiro Michitaka, Tatsuji Maeshiro, Norie Yamada, Atsushi Suetsugu, Miwa Kawanaka, Yuya Seko, Kentaro Matsuura, Akinori Okumura, Yoshitaka Fukuzawa, Masaya Sugiyama, Masashi Mizokami, Masashi Yoneda
Summary: This study found that the distribution of HBV genotypes among CHB patients in Japan has changed over time, with an increase in genotype A among young adults and a shift of genotypes B and C towards older age groups. This data provides important baseline information for comparative studies on the impact of universal HBV vaccination.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Won-Mook Choi, Gi-Ae Kim, Jonggi Choi, Gwang Hyeon Choi, Yun Bin Lee, Dong Hyun Sinn, Young-Suk Lim
Summary: This study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in patients with CHB without cirrhosis. The study found that patients with moderate baseline viral load had the highest HCC risk.
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Danny Ka-Ho Wong, Thomas Schluep, Ching-Lung Lai, Carlo Ferrari, Stephen Locarnini, Regina Cheuk-Lam Lo, Robert G. Gish, James Hamilton, Christine Wooddell, Lung Yi Mak, Bruce D. Given
Summary: The study investigated the serological, virological, and histological profiles in chronic HBV patients treated with multiple dose ARC-520. Results showed sustained and profound reductions in viral antigens and HBV RNA, with achievable HBsAg seroclearance. Immune activation was observed in some patients, and HBcAg staining was negative in all biopsied patients.
